NO20072303L - Kombinasjon av N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazo 1-2-yl]fenyl)pyridin-3-sulfonamid og et mitotisk middel for behandling av kreft. - Google Patents

Kombinasjon av N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazo 1-2-yl]fenyl)pyridin-3-sulfonamid og et mitotisk middel for behandling av kreft.

Info

Publication number
NO20072303L
NO20072303L NO20072303A NO20072303A NO20072303L NO 20072303 L NO20072303 L NO 20072303L NO 20072303 A NO20072303 A NO 20072303A NO 20072303 A NO20072303 A NO 20072303A NO 20072303 L NO20072303 L NO 20072303L
Authority
NO
Norway
Prior art keywords
methylpyrazin
sulfonamide
pyridine
methoxy
phenyl
Prior art date
Application number
NO20072303A
Other languages
English (en)
Norwegian (no)
Inventor
Francis Thomas Boyle
Andrew Mark Hughes
Donna Johnstone
John Curwen
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20072303L publication Critical patent/NO20072303L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20072303A 2004-11-25 2007-05-03 Kombinasjon av N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazo 1-2-yl]fenyl)pyridin-3-sulfonamid og et mitotisk middel for behandling av kreft. NO20072303L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0425854.7A GB0425854D0 (en) 2004-11-25 2004-11-25 Therapeutic treatment
PCT/GB2005/004483 WO2006056760A1 (fr) 2004-11-25 2005-11-23 Combinaison de n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide et d'un agent cytotoxique anti-mitotique pour le traitement du cancer

Publications (1)

Publication Number Publication Date
NO20072303L true NO20072303L (no) 2007-06-18

Family

ID=33561299

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072303A NO20072303L (no) 2004-11-25 2007-05-03 Kombinasjon av N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazo 1-2-yl]fenyl)pyridin-3-sulfonamid og et mitotisk middel for behandling av kreft.

Country Status (18)

Country Link
US (2) US20080076780A1 (fr)
EP (1) EP1819339A1 (fr)
JP (1) JP2008521782A (fr)
KR (1) KR20070089158A (fr)
CN (1) CN101065129B (fr)
AU (1) AU2005308588B2 (fr)
BR (1) BRPI0518584A2 (fr)
CA (1) CA2587140A1 (fr)
GB (1) GB0425854D0 (fr)
IL (1) IL182854A0 (fr)
MX (1) MX2007006206A (fr)
NO (1) NO20072303L (fr)
NZ (1) NZ555193A (fr)
RU (1) RU2428188C2 (fr)
SG (1) SG173415A1 (fr)
UA (1) UA92592C2 (fr)
WO (1) WO2006056760A1 (fr)
ZA (1) ZA200704104B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
EP2209501B1 (fr) 2007-10-12 2011-12-14 AstraZeneca AB Composition de Zibotentane comprenant du mannitol et de la cellulose microcristalline
PL2254570T3 (pl) 2008-02-20 2014-05-30 Actelion Pharmaceuticals Ltd Połączenie zawierające paklitaksel do leczenia raka jajnika
WO2011051894A1 (fr) 2009-10-29 2011-05-05 Aventis Pharma S.A. Nouvelle utilisation antitumorale du cabazitaxel

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) * 1976-05-11 1978-09-13 Ici Ltd Polypeptide
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5763429A (en) * 1993-09-10 1998-06-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin D analogues
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
EP0795327A1 (fr) * 1996-03-13 1997-09-17 Pfizer Inc. Utilisation de l'amlodipine pour le traitement et la prophylaxie de l'insuffisance cardiaque congestive d'origine non-ischémique
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US6827737B2 (en) * 2001-09-25 2004-12-07 Scimed Life Systems, Inc. EPTFE covering for endovascular prostheses and method of manufacture
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
GB0219660D0 (en) * 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
ATE413393T1 (de) * 2003-12-20 2008-11-15 Merck Patent Gmbh 2-(hetero-)aryl substituierte tetrahydrochinolinderivate
US7324803B2 (en) * 2005-07-07 2008-01-29 Christine Moyes Emergency settings for cellular telephones

Also Published As

Publication number Publication date
CN101065129A (zh) 2007-10-31
JP2008521782A (ja) 2008-06-26
ZA200704104B (en) 2008-09-25
NZ555193A (en) 2010-11-26
CN101065129B (zh) 2011-04-06
EP1819339A1 (fr) 2007-08-22
SG173415A1 (en) 2011-08-29
GB0425854D0 (en) 2004-12-29
RU2007123674A (ru) 2008-12-27
AU2005308588B2 (en) 2010-04-29
WO2006056760A1 (fr) 2006-06-01
US20080076780A1 (en) 2008-03-27
RU2428188C2 (ru) 2011-09-10
MX2007006206A (es) 2007-06-13
AU2005308588A1 (en) 2006-06-01
IL182854A0 (en) 2007-09-20
CA2587140A1 (fr) 2006-06-01
KR20070089158A (ko) 2007-08-30
US20100035896A1 (en) 2010-02-11
BRPI0518584A2 (pt) 2008-11-25
UA92592C2 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
ECSP056229A (es) Una composición farmacéutica que comprende formas polimórficas de 3-(4-amino-1-oxo-1.3 dyhidro-isoindol-2-il)-piperidina-2,6-diona para el tratamiento y manejo de cánceres
CY1110315T1 (el) Συνδυασμος που περιλαμβανει ν-(3-μεθοξυ-5-μεθυλπυραζιν-2-υλ)-2-(4-[1,3,4-οξαδιαζολ-2-υλ]πυριδινο-3-σουλφοναμιδιο και ενα lhrh αναλογο και/ή διφωσφονικο αλας
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
GEP20115230B (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4
EA200702116A1 (ru) Фармацевтическая дозированная форма (варианты) с контролируемым высвобождением антигипергликемического средства в комбинации с производным тиазолидиндиона
IL199673A0 (en) 5-(1,3,4- oxadiazol-2-yl)-1h-indazole and 5-(1,3,4 thiadiazol-2-yl)-1h-indazole derivatives as sgk inhibitors for the treatment of diabetes
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
CL2007003192A1 (es) Compuestos derivados de arilamidas sustituidas por tiazol u oxazol; composicion farmaceutica; y uso para el tratamiento de una enfermedad del tracto urinario.
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
NO20090834L (no) Anvendelse av azabicykloheksanderivater
CY1109529T1 (el) 2-(αμινο-υποκατεστημενες)-4-αρυλο πυραμιδινες και σχετικες ενωσεις που χρησιμευουν στην αγωγη φλεγμονωδων νοσηματων
NO20072303L (no) Kombinasjon av N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazo 1-2-yl]fenyl)pyridin-3-sulfonamid og et mitotisk middel for behandling av kreft.
IS2704B (is) Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini
MX2010003989A (es) Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.
TW200628458A (en) Metasubstituted thiazolidinones, their manufacture and use as a drug
ATE414092T1 (de) Phosphoindole als hiv-inhibitoren
CR8748A (es) Una composicion farmaceutica antimicobacteriana
HK1118276A1 (en) Ethanolamine salt of n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4- oxadiazole-2-yl]phenyl)pyridine-3-sulphonamide
ATE511842T1 (de) Kombinationstherapie zur behandlung von erhöhter miktionsfrequenz, akutem harndrang und inkontinenz
ATE524180T1 (de) Mittel zur prophylaxe oder behandlung von alkoholabhängigkeit oder drogenabhängigkeit
CY1107767T1 (el) Παραγωγο θειαζολιδινοδιονης και χρηση αυτου σαν αντιδιαβητικο
UY28499A1 (es) Tratamiento terapéutico
UA98676C2 (ru) Композиция зиботентана, содержащая маннит и микрокристаллическую целлюлозу
CU20060213A7 (es) Una composición farmacéutica antimicobacteriana
WO2009024820A3 (fr) Traitement thérapeutique 014

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application